

Direct medical costs of hospitalized patients with idiopathic pulmonary fibrosis in China

Xiaofen Zheng^{1,2*}, Bingbing Xie^{3*}, Yan Liu¹, Ming Zhu¹, Shu Zhang¹, Chengjun Ban⁴

Jing Geng³, Dingyuan Jiang³, Yanhong Ren³, Huaping Dai³, Chen Wang³

1. Department of Pulmonary and Critical Care Medicine, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China
2. The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China
3. Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital; National Clinical Research Center for Respiratory Diseases; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Peking Union Medical College; Beijing, China
4. Department of Respiration of Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China

* they contributed equally to this study.

Correspondence to:

Huaping Dai, MD, Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China–Japan Friendship Hospital, Beijing, 100029, P.R.

China. E-mail: daihuaping@ccmu.edu.cn, Tel/Fax: +86-10-84206271

Running title: Direct Medical Costs of IPF patients

Competing interests

The authors declare that they have no competing interests.

Funding:

Supported by National Key Technologies R & D Program Precision Medicine Research (No.2016YFC0901101) , CAMS Innovation Fund for Medical Sciences (CIFMS ,No. 2018-12M-1-001)and Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences (No. 2019PT320021)

Abstract

Background

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive fibrosing interstitial pneumonia of unknown cause. The incidence of IPF is increasing year by year, as well as the mortality rates, which is really a burden both for the family and the society. However few data concerning the economic burden of the patients with IPF is available , especially in China.

Objective

This study aimed to examine the direct medical costs of hospitalized patients with IPF and to determine the contributing factors.

Methods

This retrospective analysis used the cost-of-illness framework in order to analyze the direct medical costs of patients with IPF. The study used data from the pneumology department of Beijing Chao-Yang Hospital affiliated to Capital Medical University from year 2012 to 2015. The direct medical costs included drug fee, auxiliary examination fee, treatment fee and other fee. Patients' characteristics, medical treatment, and the direct medical costs were analyzed by descriptive statistics and multivariable regression.

Results

There were 219 hospitalized patients meeting the diagnosis of IPF, 91% male. The mean age was 65 years old. For the direct medical costs of hospitalized patients with IPF, the mean(SD) of the total costs per IPF patient per admission was 14882.3 (30975.8)CNY. The largest parts were the examination fee of 6034.5 (15651.2)CNY and the drug fee of 5048.9 (3855.1)CNY. By regression analysis we found that length of stay , emergency treatment, ventilator use and being a Beijing native were significantly ($P<0.05$) associated with total hospitalization costs, and the length of stay had the biggest impact. Complications or comorbidities contributed to the direct medical costs as follows: respiratory failure with 30898.3CNY ($P=0.004$), pulmonary arterial hypertension(PAH) with 26898.2CNY ($P=0.098$), emphysema with 25368.3CNY ($P=0.033$), and high blood pressure with 24659.4CNY ($P=0.026$). Using DLCO or DLCO% pred to reflect the severity of IPF, there was no significant correlation between DLCO or DLCO% pred and patients' direct medical costs. While, the worse the diffusion function, the higher the drug fee.

Conclusion

This study showed that IPF has a major impact on the direct medical costs. Thus, appropriate long-term interventions are recommended to lower the economic burden of IPF.

Keywords

Idiopathic pulmonary fibrosis, Interstitial lung disease, Direct medical costs, Economic burden of disease, Complication, Comorbidity

Strengths and limitations of this study

It was the first time in China to discuss the economic burden of diseases and its influencing factors in patients with IPF.

The results of this study might be of reference for the establishment of IPF disease-related medical policies in future.

The retrospective cross-sectional design does not allow for establishing any causal relationships.

It was a a single-center study, resulting a slightly smaller sample size. A large sample of multicenter studies is needed to confirm this.

Introduction

Idiopathic pulmonary fibrosis (IPF) is defined as a specific form of chronic fibrosing interstitial pneumonia limited to the lung, which is characterized by the pathologic pattern of usual interstitial pneumonia (UIP) and affects usually the elderly. Its etiology is unclear, but genetic factors, smoking and occupational environment exposure may be risk

factors.[1-3]

The estimates of the incidence of IPF show a wide variation in different countries, ranging from 3 to 9 per 100000 per year in North America and Europe, while in South America and Asia the incidence was reported to be lower, ranging from 1.2 to 4.16 per 100000 per year.[4] A recent study confirmed that the higher the age of the patient the higher the incidence of IPF.[5] The studies also showed that the mortality was increasing, ranging from 4.68 to 13.36 per 100000. In England and Wales, the deaths from IPF have tripled in the past 20 years .[4]

In China, there are no national population-based data on incidence, prevalence and mortality of IPF. However, data from a large ILD center showed that IPF is the most common subtype of ILD, with increasing numbers of hospitalized patients. With more patients living with IPF, it is important to understand the economic burden associated with this disease.[6]

Methods

Design and data sources

This research was designed as a retrospective cross-sectional analysis. Claims data were obtained from the IPF cohort and the database of discharged patients of Beijing Chao-Yang Hospital from the years 2012 to 2015 (219 cases). Data were retrieved from the hospital case statistics

management system, including patient characteristics, co-morbid conditions, health-care use and cost. IPF was diagnosed according to the ATS/ERS/JRS/ALAT Statement.[3] Co-morbid conditions included complications and comorbidities, which were defined as any listing of the specific co-morbid diagnosis code until and during the hospitalization. These included respiratory infections, respiratory failure, pulmonary arterial hypertension (PAH), lung cancer, high blood pressure (HBP), coronary heart disease, emphysema, diabetes, gastroesophageal reflux disease (GERD), heart failure, asthma, bronchiectasis. In our study, since all patients lacked right heart catheter monitoring, pulmonary hypertension was defined as an estimated sPAP ≥ 37 mmHg by Doppler echocardiography based on the 2009 European Society of Cardiology (ESC)/ERS PH Guideline and was divided into three grades:[7] (1) PH unlikely: TRV ≤ 2.8 m/s, sPAP ≤ 36 mmHg. (2) PH possible: TRV 2.9–3.4 m/s, sPAP 37–50 mmHg. (3) PH likely: TRV > 3.4 m/s, sPAP > 50 mmHg.

The study was reviewed and approved by the Human Ethics Review Committee of the Beijing Chao-Yang Hospital. Written informed consent was obtained from all the patients.

This study used the direct medical costs of hospitalized patient with IPF, which reflect the direct medical economic burden of these patients,

covering six categories with a total of 19 cost items (Table 1). The cost estimates were reported in Chinese Yuan (CNY) (1 US dollar \approx 6.2 CNY, 2015).

Table 1. The cost items of the direct medical costs of hospitalized patient with IPF

Categories	Cost items
Examination fee	
Laboratory diagnosis fee	Laboratory diagnosis fee
Cost of image diagnosis	Radiography fee
	Ultrasonic imaging fee
	Radionuclide imaging fee
Others	Pathological diagnosis fee
	Clinical diagnosis fee (including pulmonary function fee)
Drug fee	
Cost of antibiotics	Antibiotics fee
Cost of non-antibiotics	Western medicine fee (excluding antibiotics fee)
	Chinese patent medicine fee
	Chinese herbal medicine fee
	Blood and blood products fee
Other fees	Non-surgery treatment fee
	Surgery treatment fee
	Anesthetic fee
	Rehabilitation fee
	General medical fee

Nurse fee

Monitoring and auxiliary equipment fee

Oxygen fee, accommodation fee

Other fee

Statistical analysis

Descriptive analyses were conducted to assess HRU (Health Care Resource Utilization) of patients with IPF. Means and standard deviations (SD) were reported for continuous variables, and proportions were reported for categorical variables. The rank-sum test was used to detect the differences for continuous variables. A multiple linear regression (MLR) was utilized to estimate the impact on costs, with the use of step wise regression. Nine independent variables were entered into the regression model, including gender, age, native place reimbursement, length of stay, hospital outcome,ventilator use , and emergency treatment (as shown in Table 2) . A generalized linear model (GLM) was used to evaluate which co-morbid conditions drive total costs after accounting for patient characteristics in the total population. P-value < 0.05 was considered statistically significant.

Table 2.Variables and their measurement in the MLR

Variables	Variable assignment	Measurement
The direct medical	Y	CNY

Economic burden		
Gender	X1	1=Male, 2=Female
Age	X2	Number indicates the patient's age continue
Native place	X3	1=Native in Beijing, 2=Non-native
Reimbursement	X4	1=Medical insurance for urban workers and residents, 2 = New rural medical insurance, 3 = Free medical service, 4 =Self-paying, 5 = Others
Length of stay	X5	Number indicates the days of stay
Hospital outcome	X6	1 = Improved, 2 = Not discharged , 3 = Death
Ventilator use	X7	No =0; Yes =1
Emergency treatment	X8	No =0; Yes =1

CNY:China Yuan

Results

Patient Population

A total of 219 hospitalized patients met the diagnosis of IPF in Beijing Chao-Yang hospital from 2012 to 2015. The patients with IPF were on average 65 years old, 91% male. In terms of age, the youngest patient was 40 years old, while the oldest was 88 years old. Patients aged 61-70 years accounted for 46.6% of the patients. The population was geographically diverse, 48.9% of the patients were from Beijing (Table 3) . IPF patients

have a variety of co-morbid conditions. The prevalence of selected co-morbid conditions of IPF patients was showed in table 4.

Health Care Resource Utilization

The mean (SD) length of hospital stay was 10.1 (8) days. Procedures such as chest X-ray (16%), computed tomography (CT) scan (60%), pulmonary function tests (60%), bronchoscopy (43%) and oxygen therapy (84%) were frequently applied. Moreover, 5.9% of cases were treated with invasive or noninvasive ventilation , and 1.4% in the ICU. (Table3)

Table 3. Baseline demographics and selected healthcare utilization of IPF

Characteristic	IPF	
Subjects, n	219	100%
Male	200	91.3%
Age, years ^a	65	(8)
≤50	8	3.7%
51-60	51	23.3%
61-70	102	46.6%
71-80	43	19.6%
≥80	15	6.8%
Geographic region		
Beijing	107	48.9%
HRU		

hospitalized days ^a	10.14	(8)
chest X-ray	34	16%
CT scan	131	60%
pulmonary function tests	131	60%
bronchoscopy	94	43%
oxygen therapy	184	84%
mechanical ventilation	13	6%

IPF, idiopathic pulmonary fibrosis; SD, Standard Deviation; HRU, Health Care Resource Utilization ^a Mean (SD).

Table 4. Prevalence of selected co-morbid conditions of IPF patients

Co-morbid conditions	IPF (n=219)	
	n	%
Pulmonary infection	70	32%
Respiratory failure	43	19.6%
Pulmonary arterial hypertension	39	17.8%
Lung cancer	4	1.8%
High blood pressure	56	25.6%
Coronary artery disease	41	18.7%
Emphysema	35	16%
Diabetes	34	15.5%
GERD*	16	7.3%
Heart failure	9	4.1%
Asthma	5	2.3%

Bronchiectasis 3 1.4%

IPF, idiopathic pulmonary fibrosis; COPD, chronic obstructive pulmonary disease; GERD, gastroesophageal reflux disease;

* : 8 cases were diagnosed with 24-hour ambulatory esophageal pH and pressure recording , 8 cases were diagnosed by gastroscopy and upper gastrography.

Costs

For hospitalized patients with IPF, the mean (SD) direct medical costs was 14882.3 (30975.8) CNY per capita per admission. The results of costs of medical services for IPF are summarized in Table 5. This table shows that the examination fee, with spending of 6034.5 (15651.2) CNY in total, was the largest proportion (41%) of the direct medical costs. Table 5 also shows that the cost of antibiotics was as much as of non-antibiotics. More details are summarized in Table 5.

Table 5. The direct medical costs of hospitalized patients with IPF (CNY , per capita)

Cost items	Mean (SD)	Median (IQR)	%
Examination fee	6034.5 (3855.1)	5745.8(4105.4-7043.7)	41%
Laboratory cost	3928.2 (3089.4)	3687.5(2525.5-4556.5)	27%
Cost of imaging	935.5 (1028.3)	825.0 (530.0-1225.0)	6%
Others	1170.8 (919.8)	968.7 (439.9-1644.2)	8%
Drug fee	5048.9 (15651.2)	1347.0 (624.9-3809.9)	34%

Cost of antibiotics	2582.0 (8101.7)	25.4 (0.0-1764.1)	17%
Cost of non-antibiotics	2466.9 (8477.4)	970.9 (562.7-1873.4)	17%
Other fee	3798.9 (12751.5)	1680.9 (1058.5-2919.1)	25%
Total	14882.3 (30975.8)	9378.3 (7366.9-12122.8)	100%

SD : standard deviation; IQR : interquartile range

The direct medical costs of IPF decreased during the 4 years of this study, from 16219.2CNY in 2012 to 13513.8CNY in 2015 (Fig.1). This was mainly due to a decrease in the drug fee from 5908.0CNY to 3476.6CNY due to the policy of medicine fee decreasing.




Fig.1 The direct medical cost of hospitalized patients with IPF(2012-2015)

Regression analysis for the direct medical costs

Univariate regression analysis showed that length of hospital stay, emergency treatment, ventilator use and being a Beijing native were significantly ($P < 0.05$) associated with direct medical costs (Table 6). Multivariate regression analysis showed that the length of hospital stay had the biggest impact. The direct medical costs were not significantly associated with gender or age.

Table 6. Univariate regression analysis for the direct medical costs

Factors		N	%	Cost (CNY , per capita)	P-value
Gender	Male	200	91.3	15201.8	NS
	Female	19	8.7	11518.8	
Age	<= 50	8	3.7	8708.0	NS
	51 - 60	51	23.3	11638.7	
	61 - 70	102	46.6	13269.3	
	71 - 80	43	19.6	25657.3	
	>81	15	6.8	9283.7	
Native place	Beijing native	107	48.9	19088.5	0.047
	Non-native	112	51.1	10863.9	
Reimbursement	Medical insurance for urban workers and residents	86	39.3	21172.9	NS
	New rural medical	12	5.5	11612.0	

	insurance				
	Free medical service	33	15.1	11370.0	
	Self-paying	38	17.4	10814.7	
	The others	50	22.8	10256.7	
Ventilator use	Invasive ventilator	2	0.9	100048.5	
	Non-invasive ventilator	11	5	57904.3	0.003
	No use of ventilator	206	94.1	11758.1	
Emergency treatment	Yes	3	1.4	81626.8	
	No	216	98.6	13955.3	0.004
Hospital outcome	Improved	202	92.2	13970.5	
	Unimproved discharge	5	2.3	14919.5	NS
	Death	12	5.5	30215.8	

N: the number of patients; NS: no statistical significance

Table 7. Multivariate regression analysis for the direct medical costs

Factors	Unstandardized coefficients		Standardized coefficients	T	P-value
	B	SE	Beta		
	8.585	0.044		194.186	0.000
Length of stay	0.060	0.004	0.707	16.890	0.000
Emergency treatment	1.122	0.311	0.193	3.602	0.000
Ventilator use	0.258	0.130	0.110	1.990	0.048

Analysis of co-morbid conditions and the direct medical costs

Co-morbid conditions with a significant impact on the direct medical costs included respiratory failure (P=0.004), emphysema (P=0.033), HBP (P=0.026). For the patients with pulmonary arterial hypertension, the cost increased significantly, with P value less than 0.1. The impact on direct medical costs was greatest for respiratory failure (30898.3 CNY), being 3-fold higher than in patients without respiratory failure, followed by the direct medical costs for those with pulmonary arterial hypertension (almost 3-fold increased). (Table 8, Fig 2).

Table 8. Analysis of co-morbid diseases and the direct medical costs

Co-morbid diseases		Cost (CNY , per capita)		P-value
		Mean	SD	
Pulmonary infection	Yes	23480.2	48961.6	0.121
	No	10843.0	15630.1	
Respiratory failure	Yes	30898.3	61084.1	0.004
	No	10969.3	14877.4	
Pulmonary arterial hypertension	Yes	26898.2	63058.5	0.098
	No	12278.9	16915.5	
Heart failure	Yes	16234.8	19494.9	0.383
	No	14824.3	31403.7	
Lung cancer	Yes	8806.1	3900.9	0.586
	No	14995.3	31249.3	
Emphysema	Yes	25368.3	70895.7	0.033

	No	12887.7	13570.3	
Asthma	Yes	8287.1	2844.1	0.585
	No	15036.4	31318.2	
Bronchiectasis	Yes	14581.6	4206.0	0.770
	No	14886.5	31188.5	
HBP	Yes	24659.4	58634.6	0.026
	No	11523.3	8919.5	
Diabetes	Yes	11635.6	10979.1	0.415
	No	15479.0	33359.8	
Coronary artery disease	Yes	22547.6	61584.3	0.321
	No	13116.7	17547.7	




Fig. 2 The direct medical costs of IPF in the presence of co-morbid conditions

Relationship between lung function and costs

131 cases completed lung function tests while in hospital. Analysis of FVC, FVC% pred, DLCO, and DLCO% pred showed that FVC and FVC% pred were negatively correlated with their direct medical costs ($P < 0.05$). Moreover, the total drug costs increased significantly with increasing severity of diffusion impairment (Table 9).

DLCO% pred	Case (%)	Total cost	P-v alue	Drug cost*	P-v alue	Cost of examination	P-val ue
Normal	≥80%	5 (4%)	7491.8	756.6		4883.6	
Mild	60-80 %	21 (16%)	8839.2	768.1	0.65	6046.4	0.95
Moderate	40-60 %	35 (27%)	9150.3	1183.8		6234.3	
Severe	< 40%	70 (53%)	9784.9	1916.8		6059.4	

Table 9. Relationship between lung function and costs of IPF patient (CNY,per capita)

DLCO% pred: Carbon monoxide diffusion as a percentage of the predicted value

*:The costs were significantly different

Discussion

This study investigated health care resource utilization and the direct

medical costs of patients with IPF, from a single center database representing medical claims and health-care costs. We found that there were 219 patients diagnosed with IPF from 2012 to 2015.

The age span of IPF patients was 41-88 years old, with an average age of 65 years old and a male predominance, as previously reported.[8-10]Most importantly, we found that the direct medical economic burden of the IPF inpatients was 14882.3 CNY per patient per admission, of which the costs of examination accounted for 41% of the total, as the largest part, which was similar to a recent study in china.[11]The serious lung function decrease, having comorbidities such as respiratory failure, emphysema and high blood pressure, accompanied by length of hospital stay, emergency treatment, ventilator use were the main factors related to increased costs.

COPD is a disease with a huge economic burden. In China, mean annual direct medical costs have been estimated at around 24,372 CNY for a patient with COPD.[12]A Danish study showed that the annual net costs were €8572 for a patients with COPD, which was only one third of that of patients with IPF.[13] In the US, total direct medical costs (including inpatient services, outpatient services and medication claims) and inpatient costs for patients with IPF were found to be \$26,378 and \$9,100 per person-year, respectively, approximately 2-times higher than controls.[14]In Spain, the estimated annual costs per IPF patient with

stable disease, slow and rapid disease progression was €11,484, €20,978 and €57,759, respectively. This corresponded to a weighted average annual cost of €26,435.[15]The costs of our study was calculated from only a single hospitalization of patients with IPF during 2012 to 2015, which was more than half of the annual costs for a Chinese patient with COPD. When the medical costs of whole year including the outpatient services would be calculated together, the total costs for IPF would be much higher. In 2015, the average per capita adjusted net national income in the USA was \$ 48,967, while it was only \$ 6,352 in China.[16] All these suggested that IPF was also disease condition resulting in large economical burden in China.

Most of patients were first diagnosed as IPF following the approach of ILD during their hospitalization, so the examination fees ranked first, followed by the drug fees, accounting for one third. The Spanish study also found that a significant increase in the annual cost per patient was due to the treatment of acute exacerbation.[15]Nowadays, the treatment options of IPF are limited to the internationally recommended antifibrotic drugs pirfenidone and nintedanib.[17-19]However the costs for these drugs were not relevant to this study, because pirfenidone has not been supplied by the hospital pharmacy at the time of this study, and nintedanib was not available in China until 2018. The estimated total cost had approximately 5 times increase to around €80,000 after use of

pirfenidone and nintedanib in France.[20]So the economical burden would be increased with the use of antifibrotic drugs.

Regarding the impact of factors related to the direct medical costs, the regression analysis found that length of stay, emergency treatment, ventilator use and Beijing residency were significantly associated with total hospitalization costs. Among these factors, the length of hospital stay had the biggest impact. We know that a variety of factors affect the duration of hospitalization, including disease severity. Thus, the rational use of the allocation of medical resources can significantly reduce the direct medical economic burden on patients. In this study, 5% and 1.4% patients had ventilator use and emergency treatment during the hospitalization, which would consume more health care resources and need more complex medical therapies, inducing more costs.

The patients with IPF often have complications and other comorbidities which include pulmonary arterial hypertension, emphysema, diabetes, lung cancer, GERD, and cardiovascular disease [3,21] and require substantial health care resources, leading to increased overall burden of illness.[22]Ning Wu found that patients with IPF have a high burden of co-morbid conditions and HRU compared to non-IPF patients.[23]Collard et al found that pulmonary infection, coronary artery disease, diabetes and heart failure were the most prevalent comorbidity and all were

significantly more common in IPF than in controls.[14]In this study, which was a cross-sectional review,there were only 4 patients with lung cancer in IPF and only 19 patients completed the 24-hour ambulatory esophageal pH and pressure recording.As a result,the GERD and lung cancer prevalence was lower than the previews study and the group was too small to be statistically significant.[24,25]As our study showed, pulmonary infection, high blood pressure, coronary artery disease, respiratory failure, diabetes, emphysema and pulmonary arterial hypertension were the most prevalent comorbidity codes in the IPF.Another study in china had showed that the prevalence of IPF patients with pulmonary arterial hypertension and emphsema was 29% and 42% respectively.[26]The costs of IPF patients with respiratory failure and pulmonary arterial hypertension were found to be higher than for other patients. This results are similar to a previous study.[27]Most series have shown a higher mortality when pulmonary arterial hypertension is present in IPF patients.[28-29]Thus, an IPF patient with pulmonary arterial hypertension will raise the economic burden.

There are several limitation. firstly, this is a retrospective research from a single center. Secondly, only the costs for hospitalization and not annual costs were analyzed. Thirdly, the costs of antifibrotic drugs were not included due to lack of available drugs during the study time.

Conclusion

As the prevalence of IPF appears to be rising along with an increasing burden on our healthcare system, a substantial increase in public awareness and research funding will be necessary to address the unmet needs and reduce the clinical and economic burden of this still incurable illness.

Acknowledgments

We would like to acknowledge the medical record room and statistics office in Beijing Chaoyang Hospital for providing us with data support. Thanks also to our entire team for their assistance in data collection and processing. At the same time, I would like to thank the DR. Costabel for guiding the article. At last but not least, the authors would like to thank study participants for their time, patience and involvement in the study.

Reference

[1] Cordier JF, Cottin V. Neglected evidence in idiopathic pulmonary fibrosis: From history to earlier diagnosis. *Eur Respir J* 2013;42(4):916-23.

[2] Pinheiro GA, Antao VC, Wood JM, et al. Occupational risks for idiopathic pulmonary fibrosis mortality in the United States. *Int J Occup Environ Health* 2008;14(2):117-23.

[3] Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management. *Am J Respir Crit Care Med* 2011;183(6):788-824.

[4] Hutchinson J, Fogarty, A. Global incidence and mortality of idiopathic pulmonary

fibrosis: a systematic review. *Eur Respir J* 2015;46(3):795-8065

[5] Raghu G, Chen SY. Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence and survival, 2001–11. *Lancet Respir Med* 2014; 2: 566–72.

[6] Ban C, Yan W, Xie B, et al. Spectrum of Interstitial Lung Disease in China from 2000 to 2012. *Eur Respir J* 2018;52(3). pii: 1701554.

[7] Galiè N, Hoesper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). *Eur Heart J* 2009;30:2493-537.

[8] Cai M, Zhu M, Ban C, et al. Clinical features and outcomes of 210 patients with idiopathic pulmonary fibrosis. *Chin Med J* 2014;127(10):1868-73.

[9] Coultas DB, Zumwalt RE, Black WC, et al. The epidemiology of interstitial lung diseases. *Am J Respir Crit Care Med* 1994; 150:967–972

[10] Raghu G, Weycker D, Edelsberg J, et al. Incidence and prevalence of idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med* 2006;174: 810–816.

[11] Xuan J, Lu Y, Ren M, et al. Direct Economic Burden of Idiopathic Pulmonary Fibrosis in China. *Chin J Pharm Econ* 2019;14(6): 9-12

[12] Li M, Wang F, Chen R, et al. Factors contributing to hospitalization costs for patients with COPD in China: a retrospective analysis of medical record data. *Int J Chron Obstruct Pulmon Dis* 2018;13:3349-3357.

[13] Hilberg O, Bendstrup E, Ibsen R, et al. Economic consequences of idiopathic pulmonary fibrosis in Denmark. *ERJ Open Res* 2018; 4(2):00045-2017.

[14] Collard HR, Ward AJ. Burden of illness in idiopathic pulmonary fibrosis. *J Med Econ* 2012;12(5):829-835

[15] Morell F, Esser D. Treatment patterns, resource use and costs of idiopathic pulmonary fibrosis in Spain - results of a Delphi Panel. *BMC Pulm Med* 2016;16(1):7

[16] <https://data.worldbank.org.cn>

[17] King Talmadge E, Bradford Williamson Z. A Phase 3 Trial of Pirfenidone in

Patients with Idiopathic Pulmonary Fibrosis. *New England Journal of Medicine* 2014;370(22):2083-2092

[18] Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. *N Engl J Med* 2014; 370: 2071–2082

[19] Wilson KC, Raghu G. The 2015 guidelines for idiopathic pulmonary fibrosis: an important chapter in the evolution of the management of patients with IPF. *Eur Respir J* 2015 Oct;46(4):883-6

[20] Porte F, Cottin V, Catella L, et al. Health economic evaluation in idiopathic pulmonary fibrosis in France. *Curr Med Res Opin* 2018 Oct;34(10):1731-1740

[21] Vancheri C, Cottin V, Kreuter M, et al. IPF, comorbidities and management implications. *SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES* 2015; 32(Suppl. 1): 17-23

[22] Lee AS, Mira-Avendano I, Ryu JH, et al. The burden of idiopathic pulmonary fibrosis: an unmet public health need. *Respir Med* 2014 Jul;108(7):955-67.

[23] Wu Ning, Yu Yanni F, Chuang Chien-Chia, et al. Healthcare resource utilization among patients diagnosed with idiopathic pulmonary fibrosis in the United States. *Journal of Medical Economics* 2015 Apr;18(4): 249-257

[24] Gao F, Hobson AR, Shang ZM, et al. The prevalence of gastro-esophageal reflux disease and esophageal dysmotility in Chinese patients with idiopathic pulmonary fibrosis. *BMC Gastroenterology* (2015) 15:26

[25] Liu Y, Zhu M, Geng J, et al. Incidence and radiologic-pathological features of lung cancer in idiopathic pulmonary fibrosis. *Clin Respir J* 2018 12(4) : 1700-1705

[26] Cai M, Zhu M, Ban C, et al. Clinical features and outcomes of 210 patients with idiopathic pulmonary fibrosis. *Chin Med J* 2014;127(10):1868-73

[27] Anna Lena Frank, Michael Kreuter, Larissa Schwarzkopf. Economic burden of incident interstitial lung disease (ILD) and the impact of comorbidity on costs of care. *Respiratory Medicine* 2019;152:25–31

[28] Lettieri CJ, Nathan SD, Barnett SD, et al. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. *Chest* 2006;129 : 746-52

[29]Nadrous HF, Pelikka PA, Krowka MJ, et al.The impact of pulmonary hypertension on survival in patients with idiopathic pulmonary fibrosis. Chest 2005;128 (Suppl.6) :616S-617S

